KAN fundamentals
Key facts
Market capitalization—
Founded—
CEO—
Website—
About
Kancera AB engages in the research, development, and sale of drug candidates to pharmaceutical companies. It focuses on Fractalkine program which develops a candidate drugs for treatment of severe inflammatory diseases and cancer. The company was founded by Hakan Mellstedt on April 28, 2010 and is headquartered in Solna, Sweden.
Valuation
Fundamental metrics to determine fair value of the stock
Growth and Profitability
Company’s recent performance and margins
Dividends
Dividend yield, history and sustainability
KAN does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future
Financial health
Financial position and solvency of the company